# Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome

> **NCT00057967** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 37 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** alemtuzumab

## Key facts

- **NCT ID:** NCT00057967
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2007-06-26
- **Final completion:** 2010-07-26
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2019-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057967, "Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00057967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*